drugset
drugset / Trial / NCT05895773

Oro-nasal Decontamination to Prevent Ventilator-associated Pneumonia

NCT05895773 ↗

Phase 2/3 Completed 78 enrolled Menoufia University
RandomizedParallel-groupQuadruple-blindPrevention

Summary

It has been shown that oral hygiene reduces the incidence of ventilator-associated pneumonia (VAP). The nasopharynx is considered to be an important source of contaminated micro aspiration to the lung however, the effect of nasopharyngeal decontamination on VAP has not been yet investigated. The investigators hypothesized that decontamination of oral and nasopharyngeal cavities with combined Povidone Iodine and glycyrrhizin would remarkably reduce the incidence of VAP.

Timeline

Start
2023-06-24
Primary completion
2023-11-24
Completion
2023-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Povidone-Iodine Other / unclassified 0.5 % Intranasal
Subject glycyrrhizin acid Unknown 2.5 mg/ml Intranasal

Indications

No indication recorded.